Groove Biopharma, Inc.: Series B $6M

Posted in I - Series B, Q - 4Q11, R - NORTH WEST, X - Antiinfective, X - Fibrosis, X - Oncology, X - miRNA, XX - WA

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Mar

2010

Promedior, Inc.: Series C $12M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Fibrosis, X - Inflammation, XX - PA

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

Nov

2008

Stromedix, Inc.: Series B $25M

Posted in I - Series B, Q - 2Q08, R - NORTH EAST, X - Fibrosis, X - Oncology, X - Organ Failure, X - Renal

Stromedix (Cambridge, MA) development-stage biotechnology company focused on therapies for fibrosis, closed a $25M Series B financing. Participants include New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, Atlas Venture and Frazier Healthcare Ventures.

to top of page...